 |
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a...
Hashtag.net.au
In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...
Hashtag.net.au
The early developmental years of a child's life represent a critical window for neurological growth, behavioural shaping, and language acquisition. During this formative phase, the ability to interpre...
Hashtag.net.au
Finding the right family dentist in Sydney is one of the most important health decisions you can make for your household. With hundreds of practices spread across the city — from Beecroft to Bondi, Pa...